(Q34108009)

31 July 2017

1 reference

title

Chemotherapy for androgen- independent prostate cancer: myth or reality (English)

1 reference

31 July 2017

Kelly WK

1 reference

31 July 2017

Slovin SF

series ordinal

1 reference

31 July 2017

publication date

1 September 2000

1 reference

31 July 2017

1 reference

inferred from page(s)

published in

Current Oncology Reports

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

394-401

1 reference

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

31 July 2017

cites work

1 reference

12 December 2020

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

1 reference

12 December 2020

Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer

1 reference

12 December 2020

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

12 December 2020

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

1 reference

12 December 2020

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

12 December 2020

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

12 December 2020

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

1 reference

12 December 2020

Blocking of collagenase secretion by estramustine during in vitro tumor cell invasion.

1 reference

12 December 2020

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

12 December 2020

Clinical trials in relapsed prostate cancer: defining the target

1 reference

12 December 2020

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 December 2020

A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

1 reference

12 December 2020

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

12 December 2020

Plasma Concentrations of Estramustine Phosphate and Its Major Metabolites in Patients with Prostatic Carcinoma Treated with Different Doses of Estramustine Phosphate (Estracyt®)

1 reference

12 December 2020

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

12 December 2020

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

1 reference

12 December 2020

Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation

1 reference

12 December 2020

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

12 December 2020

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

12 December 2020

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

1 reference

12 December 2020

A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

12 December 2020

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

12 December 2020

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

12 December 2020

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

12 December 2020

Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines

1 reference

12 December 2020

10.1007/S11912-000-0058-0

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1051983233

0 references

1 reference